GeoVax CEO awarded 29,300 stock options

GeoVax Labs, Inc. reported that President and CEO David A. Dodd received a grant of stock options classified as a derivative security.

Rhea-AI Filing Summary

GeoVax Labs, Inc. reported that President and CEO David A. Dodd received a grant of stock options classified as a derivative security. The award covers 29,300 stock options, each exercisable for one share of common stock at an exercise price of $1.18 per share, with no cash paid at grant.

The options expire on June 17, 2036 and become exercisable in three equal annual installments on the first three anniversaries of the grant date. Following this grant, Dodd holds 29,300 stock options directly as reported in this filing, reflecting a routine compensation-related award rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 29,300 shares

Grant/Award 1 txn

Insider DODD DAVID A

Role President, CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	29,300	$0.00	$0.00

Holdings After Transaction: Stock Option — 29,300 contracts (Direct)

Footnotes (1)

1. F1. Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant.

Key Figures

Stock options granted: 29,300 options Exercise price: $1.18 per share Expiration date: June 17, 2036 +2 more

5 metrics

Stock options granted 29,300 options Grant to President and CEO David A. Dodd

Exercise price $1.18 per share Strike price for the 29,300 options

Expiration date June 17, 2036 Option term for the granted stock options

Underlying shares 29,300 shares Common stock underlying the stock options

Holdings after grant 29,300 options Total derivative holdings following this transaction

Key Terms

Stock Option, exercise price, Grant, award, or other acquisition, derivative security, +1 more

5 terms

Stock Option financial

"security_title: "Stock Option" and underlying_security_title: "Common Stock""

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion_or_exercise_price: "1.1800" indicates the option exercise price per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

derivative security financial

"transaction_type: "derivative" classifies the stock option as a derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

vests in three equal annual installments financial

"Footnote: "Stock option becomes exercisable in three equal annual installments""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did GeoVax Labs (GOVX) disclose in this Form 4 for David A. Dodd?

GeoVax Labs disclosed that President and CEO David A. Dodd received a grant of 29,300 stock options. These options are part of his compensation and give the right to buy common shares at a fixed exercise price in the future, subject to vesting.

How many stock options did GeoVax CEO David A. Dodd receive in this filing?

David A. Dodd received 29,300 stock options linked to GeoVax Labs common stock. Each option can convert into one share once vested and exercised, giving him potential future ownership without any cash outlay at the time the award was granted.

What is the exercise price and expiration date of David A. Dodd’s GeoVax stock options?

The stock options granted to David A. Dodd have an exercise price of $1.18 per share and expire on June 17, 2036. This means he can choose to buy shares at $1.18 any time after vesting and before the expiration date.

How do the newly granted GeoVax options to David A. Dodd vest over time?

The options vest in three equal annual installments on the first three anniversaries of the grant date. This staggered vesting schedule encourages longer-term service, as Dodd gains exercisable rights to only one-third of the options each year over three years.

Is this GeoVax Form 4 transaction an open-market buy or sell of GOVX shares?

No, this Form 4 reports a compensation-related grant of stock options, not an open-market buy or sell. The options were awarded at no cost and become exercisable later, so there is no immediate market transaction in GeoVax common stock.

How many GeoVax stock options does David A. Dodd hold after this grant?

After the reported grant, David A. Dodd holds 29,300 stock options directly as shown in the filing. These options represent his current derivative position from this award, tied to an equal number of underlying GeoVax common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 04:16 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DODD DAVID A

(Last) (First) (Middle)

1955 LAKE PARK DRIVE

SUITE 300

(Street)

SMYRNA GEORGIA 30080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GeoVax Labs, Inc. [ GOVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$1.18	06/17/2026		A		29,300		(1)	06/17/2036	Common Stock	29,300	$0	29,300	D

Explanation of Responses:

1. Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant.

	/s/ David A. Dodd	06/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)